Exposure-response analysis showed that the selected doses for this placebo-controlled Phase II study were below the therapeutic range for adequate tic reduction in the majority of pediatric subjects. For the subset of subjects with pharmaceutical exposure in the appropriate range, there was a substantial reduction in tics (e.g., -11.3 to -13.7 points on the YGTSS). For subjects with sub-therapeutic exposure, tic reduction was comparable to placebo (e.g., -4.7 to -8.3 points on the YGTSS). In this study, adverse events were consistent with those observed in previous INGREZZA studies. There were a total of four discontinuations due to adverse events, two in each of the placebo and INGREZZA arms.
"This study showed that we underestimated the INGREZZA dose needed for the pediatric population but also provided us with a clear-cut view into the level of dosing required for future studies," said
About T-Force GREEN
The T-Force GREEN study was a randomized, double-blind, placebo-controlled, multi-dose, parallel group, Phase II study of 98 children and adolescents. Pediatric Tourette syndrome patients received once-daily dosing of INGREZZA or placebo during a six-week treatment period to assess the safety, tolerability and efficacy of INGREZZA. The primary endpoint of this study was the change-from-baseline of the Yale Global Tic Severity Scale between placebo and active treatment groups at the end of week six. The study assessed two doses of INGREZZA for each of the child and adolescent study arms.
Additionally, the Company is also conducting an open-label, fixed-dose study of INGREZZA in up to 180 subjects with Tourette syndrome. This study has recently completed enrollment and was designed to enroll up to 90 children and adolescents and up to 90 adults who have completed either of the two placebo-controlled Tourette syndrome clinical trials: T-Force GREEN or T-Forward. This Phase II study will assess the long-term safety and tolerability of INGREZZA in children and adults with Tourette syndrome.
About Tourette Syndrome
Tourette syndrome is a neurological disorder that consists of rapid, non-rhythmic stereotyped motor and vocal tics. Motor tics are typically characterized by facial grimacing, head jerks, extremity movements and other dystonic movements. Vocal tics typically include grunting, throat clearing, and repeating words and phrases. The average age of onset for Tourette syndrome is six years, with symptoms reaching their peak severity at approximately age ten. Tourette syndrome is more commonly diagnosed in males than females and may be associated with attention deficit hyperactivity disorder and obsessive compulsive disorder.
About INGREZZA
INGREZZA, a selective VMAT2 inhibitor, is the first and only product approved for the treatment of adults with tardive dyskinesia (TD). INGREZZA inhibits VMAT2 and is thought to work by reducing the amount of dopamine released in a region of the brain that controls movement and motor function, helping to regulate nerve signaling in adults with TD. VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release in presynaptic neurons. INGREZZA, developed in Neurocrine's laboratories, is novel in that it selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic, or muscarinic receptors. Additionally, INGREZZA can be taken once-daily, and together with psychiatric medications such as antipsychotics or antidepressants.
Conference Call and Webcast Today at
Neurocrine will hold a live conference call and webcast today at
About
In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with INGREZZA (valbenazine) development for Tourette syndrome. Specifically, the risks and uncertainties the Company faces include risks that INGREZZA development activities may not be completed on time or at all; risks that INGREZZA development activities may not be completed or may be delayed for regulatory or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that INGREZZA is safe, tolerable or effective in the Tourette syndrome population, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that regulatory submissions may not occur or be submitted in a timely manner; risks that INGREZZA may not obtain regulatory approval for Tourette syndrome, or that the
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neurocrine-announces-phase-ii-results-of-vmat2-inhibitor-ingrezza-for-treatment-of-tourette-syndrome-300462596.html
SOURCE
IR Contact: IR@neurocrine.com